TY - JOUR
T1 - Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia
AU - Durier, N.
AU - Yunihastuti, Evy
AU - Ruxrungtham, K.
AU - Kinh, N. V.
AU - Kamarulzaman, A.
AU - Boettiger, D.
AU - Widhani, Alvina
AU - Avihingsanon, A.
AU - Huy, B. V.
AU - Syed Omar, S. F.B.
AU - Sanityoso, A.
AU - Chittmittrapap, S.
AU - Dung, N. T.H.
AU - Pillai, V.
AU - Suwan-Ampai, T.
AU - Law, M.
AU - Sohn, A. H.
AU - Matthews, G.
N1 - Funding Information:
Abbott RealTime HCV assay and RealTime HCV GT II assay were procured from Abbott Molecular at a discounted rate. IL28B Investigational Use Only assay was donated by Abbott Molecular. The study group has received drug donations (Peg-IFN and RBV) from Merck Sharp and Dohme for a related study of treatment of HCV infection. DB is supported by a research grant from Gilead Sciences. GM has received grants support from Abbvie, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme. ML has received grants support from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, ViiV HealthCare. He has received DSMB sitting fees from Sirtex Pty Ltd.
Publisher Copyright:
© 2016 John Wiley & Sons Ltd
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Data on markers of hepatitis C virus (HCV) disease in HIV-HCV-coinfected patients in resource-limited settings are scarce. We assessed HCV RNA, HCV genotype (GT), IL28B GT and liver fibrosis (FibroScan®) in 480 HIV-infected patients with positive HCV antibody in four HIV treatment centres in South-East Asia. We enrolled 165 (34.4%) patients in Jakarta, 158 (32.9%) in Bangkok, 110 (22.9%) in Hanoi and 47 (9.8%) in Kuala Lumpur. Overall, 426 (88.8%) were male, the median (IQR) age was 38.1 (34.7-42.5) years, 365 (76.0%) reported HCV exposure through injecting drug use, and 453 (94.4%) were on combination antiretroviral therapy. The median (IQR) CD4 count was 446 (325-614) cells/mm3 and 208 (94.1%) of 221 patients tested had HIV-1 RNA <400 copies/mL. A total of 412 (85.8%) had detectable HCV RNA, at a median (IQR) of 6.2 (5.4-6.6) log10 IU/mL. Among 380 patients with HCV GT, 223 (58.7%) had GT1, 97 (25.5%) had GT3, 43 (11.3%) had GT6, eight (2.1%) had GT4, two (0.5%) had GT2, and seven (1.8%) had indeterminate GT. Of 222 patients with IL28B testing, 189 (85.1%) had rs12979860 CC genotype, and 199 (89.6%) had rs8099917 TT genotype. Of 380 patients with FibroScan®, 143 (37.6%) had no/mild liver fibrosis (F0-F1), 83 (21.8%) had moderate fibrosis (F2), 74 (19.5%) had severe fibrosis (F3), and 79 (20.8%) had cirrhosis (F4). One patient (0.3%) had FibroScan® failure. In conclusion, a high proportion of HIV-HCV-coinfected patients had chronic HCV infection. HCV GT1 was predominant, and 62% of patients had liver disease warranting prompt treatment (≥F2).
AB - Data on markers of hepatitis C virus (HCV) disease in HIV-HCV-coinfected patients in resource-limited settings are scarce. We assessed HCV RNA, HCV genotype (GT), IL28B GT and liver fibrosis (FibroScan®) in 480 HIV-infected patients with positive HCV antibody in four HIV treatment centres in South-East Asia. We enrolled 165 (34.4%) patients in Jakarta, 158 (32.9%) in Bangkok, 110 (22.9%) in Hanoi and 47 (9.8%) in Kuala Lumpur. Overall, 426 (88.8%) were male, the median (IQR) age was 38.1 (34.7-42.5) years, 365 (76.0%) reported HCV exposure through injecting drug use, and 453 (94.4%) were on combination antiretroviral therapy. The median (IQR) CD4 count was 446 (325-614) cells/mm3 and 208 (94.1%) of 221 patients tested had HIV-1 RNA <400 copies/mL. A total of 412 (85.8%) had detectable HCV RNA, at a median (IQR) of 6.2 (5.4-6.6) log10 IU/mL. Among 380 patients with HCV GT, 223 (58.7%) had GT1, 97 (25.5%) had GT3, 43 (11.3%) had GT6, eight (2.1%) had GT4, two (0.5%) had GT2, and seven (1.8%) had indeterminate GT. Of 222 patients with IL28B testing, 189 (85.1%) had rs12979860 CC genotype, and 199 (89.6%) had rs8099917 TT genotype. Of 380 patients with FibroScan®, 143 (37.6%) had no/mild liver fibrosis (F0-F1), 83 (21.8%) had moderate fibrosis (F2), 74 (19.5%) had severe fibrosis (F3), and 79 (20.8%) had cirrhosis (F4). One patient (0.3%) had FibroScan® failure. In conclusion, a high proportion of HIV-HCV-coinfected patients had chronic HCV infection. HCV GT1 was predominant, and 62% of patients had liver disease warranting prompt treatment (≥F2).
KW - Asia
KW - HIV
KW - chronic infection
KW - fibrosis
KW - hepatitis C virus
UR - http://www.scopus.com/inward/record.url?scp=85006415465&partnerID=8YFLogxK
U2 - 10.1111/jvh.12630
DO - 10.1111/jvh.12630
M3 - Article
C2 - 27917597
AN - SCOPUS:85006415465
SN - 1352-0504
VL - 24
SP - 187
EP - 196
JO - Journal of Viral Hepatitis
JF - Journal of Viral Hepatitis
IS - 3
ER -